Vital Therapies Inc  

(Public, NASDAQ:VTL)   Watch this stock  
Find more results for vital
+0.17 (2.65%)
After Hours: 6.59 0.00 (0.00%)
Jul 27, 4:42PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.31 - 6.64
52 week 2.81 - 20.99
Open 6.42
Vol / Avg. 0.00/94,162.00
Mkt cap 206.09M
P/E     -
Div/yield     -
EPS -1.80
Shares 30.98M
Beta     -
Inst. own 33%
Aug 2, 2016
Q2 2016 Vital Therapies Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 2, 2016
Q2 2016 Vital Therapies Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 12, 2016
Vital Therapies Inc at Cantor Fitzgerald Healthcare Conference
Jun 10, 2016
Vital Therapies Inc at Jefferies Healthcare Conference
May 10, 2016
Q1 2016 Vital Therapies Inc Earnings Call
May 9, 2016
Q1 2016 Vital Therapies Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -44.72% -52.77%
Return on average equity -47.96% -57.84%
Employees 78 -
CDP Score - -


15010 Avenue of Science Ste 200
SAN DIEGO, CA 92128-3421
United States - Map
+1-858-6736840 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.

Officers and directors

Terence E. Winters Ph.D. Co-Chairman of the Board, Chief Executive Officer
Age: 72
Bio & Compensation  - Reuters
Muneer A. Satter J.D., M.B.A. Co-Chairman of the Board, Lead Director
Age: 54
Bio & Compensation  - Reuters
Michael V. Swanson M.B.A. Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Robert A. Ashley Executive Vice President, Chief Technical Officer
Age: 57
Bio & Compensation  - Reuters
Duane Nash M.D, J.D. Executive Vice President, Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Aron P. Stern M.B.A. Chief Administrative Officer
Age: 61
Bio & Compensation  - Reuters
Andrew Henry Vice President - Clinical Operations
Age: 50
Bio & Compensation  - Reuters
Andrea Loewen-Rodriguez Vice President - Regulatory Affairs and Quality Assurance
Age: 47
Bio & Compensation  - Reuters
Richard Murawski Vice President - Manufacturing
Age: 66
Bio & Compensation  - Reuters
John M. Dunn General Counsel, Secretary
Age: 63
Bio & Compensation  - Reuters